Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T7MN
|
|||
| Former ID |
DIB006116
|
|||
| Drug Name |
ZYH-1
|
|||
| Synonyms |
Metabolism disorder treatment, Zydus-Cadila; PPAR alpha/gamma modulator (dyslipdemia), Zydus-Cadila
Click to Show/Hide
|
|||
| Indication | Lipid metabolism disorder [ICD-11: 5C52.Z] | Phase 3 | [1] | |
| Company |
Zydus-Cadila Group
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 g compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther. 2014 Feb;16(2):63-71. | |||
| REF 2 | Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.